NuVasive Has More To Offer Than The Street Thinks

There are definitely some concerns that NuVasive (NUVA) management still has to address, but these shares have done alright since my last bullish write-up - rising more than 20% and more than doubling the performance of the broader med-tech space and outperforming Globus (GMED), though not keeping pace with the recent melt-ups of Alphatec (ATEC) or SeaSpine (SPNE).

With some meaningful recent product releases, a value-adding deal, and the upcoming Pulse launch, I believe the company can reverse some of its recent share losses and rebuild some positive sentiment. Undervalued on the basis of cash flow, revenue growth, and margins, I believe these shares should trade into the $70s.

 

Click the link for the full article: 

NuVasive Has More To Offer Than The Street Thinks